Company “C” has developed an antimicrobial peptide C4. The discovery has been shown to significantly reduce the resistance and side effects of existing antimicrobial substances for acne treatment and demonstrates potent antimicrobial activity.
Existing antimicrobial ingredients and antibiotics applied to skin care products that target acne-prone skin and acne medications cause side effects such as redness, contact dermatitis, vomiting, and fever in some users. There have been noted cases of antibiotic resistance observed also.
Company “C” developed a new paradigm of antimicrobial peptide C4 that is extracted from milk-derived protein. This was conducted through extensive research and development after the shortcomings of existing ingredients with temporary effects on acne began surfacing.
Antimicrobial peptide C4, which selectively attacks the cell membrane of pathogenic bacteria, exhibits antimicrobial activity
Antimicrobial peptide C4, a new antimicrobial ingredient developed by Company “C”, demonstrates a potent inhibitory effect against five pathogenic bacteria, including C. acnes, even in low concentrations. It is claimed that antimicrobial peptide C4 has a mechanism that selectively attacks the cell membranes that protect harmful bacteria. This explains its powerful inhibitory effects.
Antimicrobial peptide C4 targets only pathogenic bacteria while leaving beneficial bacteria on the skin.
Existing antibiotics and antimicrobial ingredients have the drawback of killing not only harmful bacteria that cause skin problems, but also beneficial bacteria that serve as a defensive barrier during antimicrobial action. When all beneficial bacteria are killed in this manner, the skin becomes easily irritated or breaks down in response to even mild stimulation, which can result in side effects and recurring problems. In addition to this problem, antimicrobial peptide C4 was developed to protect beneficial bacteria regardless of concentration by introducing a technology that selectively kills harmful skin bacteria only. As only harmful bacteria are killed while keeping beneficial bacteria alive, the risk factors for epidermal side effects are minimised significantly and the defence barrier is preserved.
Percent Science, a bio-cosmetic brand, has commercialized antimicrobial peptide C4 with an epidermally-applied product.
As antimicrobial peptide C4 has excellent antimicrobial effects, it was difficult to achieve commercial stability and maximum efficacy. However, the bio-cosmetic brand Percent Science has successfully commercialized antimicrobial peptide C4 as a skin care product through the use of biotechnology metrics such as cytotoxicity tests, substance stabilization tests, in-vitro cell efficacy tests, TDDS transdermal drug delivery systems, and human application tests.
